除了血糖控制之外:性别差异塑造了美国的葡萄糖类-1受体激动剂利用情况
1Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, TX.
Journal of managed care & specialty pharmacy
|February 4, 2026
概括
类似葡萄糖-1受体激动剂 (GLP-1RAs) 的使用正在增加,特别是在女性中. 虽然2型糖尿病是一个关键因素,但肥胖症的影响越来越大,尤其对女性来说,这突显了对性别特定护理的需要.
科学领域:
- 药理学和内分泌学 药理学和内分泌学
- 公共卫生和流行病学
- 基于性别的医学
背景情况:
- 葡萄糖类-1受体激动剂 (GLP-1RAs) 越来越多地用于治疗2型糖尿病 (T2DM) 和肥胖症.
- 在GLP-1RA利用中存在显著的性别差异,但在美国,有助于因素仍未得到充分研究.
- 了解这些差异对于公平的患者护理和治疗优化至关重要.
研究的目的:
- 调查影响美国成年人GLP-1RA使用的时间和性别特定因素.
- 分析塞马格卢提德在慢性体重管理中获得批准之前和之后的趋势.
- 确定GLP-1RA在不同的人口和健康状况中利用的关键预测因素.
主要方法:
- 对美国成年人 (≥18岁) 的2019-2022医疗支出小组调查数据的分析.
- 通过处方药档案识别GLP-1RA使用情况.
- 根据时间和性别对用户特征的统计比较,包括多变量后勤回归和T2DM的子组分析.
主要成果:
- 从2019-2020年到2021-2022年,GLP-1RA的使用显著增加,男性和女性的患病率相似.
- 2型糖尿病 (T2DM) 仍然是最强的预测因素,但其比例下降,特别是在女性中.
- 肥胖成为一个重要因素,随着时间的推移,特别是女性中,其联系得到了加强;抑郁症也与女性的使用率更高有关.
结论:
- 在美国,GLP-1RA的使用量正在上升,女性的使用量显著增加.
- 肥胖是一个越来越重要的因素,特别是对于女性来说,与T2DM一起.
- 影响GLP-1RA使用的临床和心理社会因素需要针对糖尿病和肥胖症采取性别敏感的管理策略.
相关概念视频
Glucagon-like Receptor Agonists
980
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
980
Drug-Receptor Interaction: Agonist
4.1K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.1K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
1.0K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.0K
Hypoglycemia and Glucagon
990
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
990
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
509
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
509
Molecular Shape and Polarity
75.8K
Dipole Moment of a Molecule
75.8K


